Vaccines

>

Latest News

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.
Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC

April 2nd 2024

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.
Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024

COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy
COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy

March 2nd 2023

Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.
Cervical Cancer and Grade 3 Cervical Intraepithelial Neoplasia Incidence Reduced in Young, HPV-Vaccinated Individuals

November 4th 2021

UV1 Cancer Vaccine Receives FDA Fast Track Designation in Melanoma
UV1 Cancer Vaccine Receives FDA Fast Track Designation in Melanoma

November 3rd 2021

Video Interviews
Podcasts

More News

Decline in HPV-Related Cervical Cancer May Inform Screening and Vaccination Guidance for Other Tumor Types

Decline in HPV-Related Cervical Cancer May Inform Screening and Vaccination Guidance for Other Tumor Types

Audrey Sternberg
May 20th 2021

Seventeen years of data indicate that HPV-related cervical cancer incidence is declining, but other tumors related to the virus persist.

Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy

Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy

Mehmet Sitki Copur, MD
April 21st 2021

A review of mRNA vaccine technology by ONCOLOGY® editorial board member Mehmet Sitki Copur, MD, FACP, explains the basis for progress in this field and reviews a number of new trials using this technology.

Messenger RNA: A Technology of the Moment

Messenger RNA: A Technology of the Moment

Howard S. Hochster, MD
April 16th 2021

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the development of mRNA technology, especially as it applies to vaccines against COVID-19.

Survey of Patients With Comorbid Conditions Shows Vaccine Hesitancy Is Common

Survey of Patients With Comorbid Conditions Shows Vaccine Hesitancy Is Common

Audrey Sternberg
April 14th 2021

In a sample of patients with comorbid conditions that included patients with cancer, nearly 20% of patients reported having reservations about receiving the COVID-19 vaccine.

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

Audrey Sternberg
February 28th 2021

The first single shot COVID-19 vaccine, and the third overall, to receive Emergency Use Authorization will start shipping to all parts of the United States immediately following a meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee.